Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

336 - Dependence of fluorodeoxyglucose avidity on tumour size in non-small cell lung cancer


19 Dec 2015


Poster presentation 1


Pei Ding


Annals of Oncology (2015) 26 (suppl_9): 153-155. 10.1093/annonc/mdv534


P. Ding, J. Tai, P. Manders, E. Stone, B. Ho, R. Epstein

Author affiliations

  • Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, 2010 - Darlinghurst/AU


Abstract 336


High standard uptake value (SUVmax) for fluorodeoxyglucose (FDG) avidity in primary lung cancer is associated with aggressive disease. Here we have hypothesised that correction of SUVmax for tumour size enables clinically useful identification of small high-SUVmax lung tumours with bad prognosis, and/or large low-SUVmax tumours with good prognosis.


Data from 615 patients were downloaded from the lung cancer database 2007-2014. Of these, we identified 204 cases of adenocarcinoma or squamous cell carcinoma (SCC) for which correlative FDG-PET scan data were available. To assess the relationship of SUVmax to histology and stage independent of size, we derived a new parameter, size-corrected SUV (scSUV). Statistics were generated using SPSS software.


A linear relationship was shown between SUVmax and tumour size (p < 0.0001, R = 0.6); moreover, late-stage tumours were associated with higher SUVmax (p < 0.001) and size (p = 0.001) than early-stage tumours. Both a higher SUVmax (p = 0.001) and size (p < 0.001) were found for SCC vs. adenocarcinoma. When these relationships with stage and histology were re-analyzed using scSUV instead of SUVmax, however, no significant trend was evident (p = 0.98 and p = 0.1, respectively). Consistent with this, very few small high-SUVmax or large low-SUVmax tumours could be identified.


We submit that primary lung cancer SUVmax does not vary independently of tumour size to any clinically useful extent. This suggests in turn that primary lung tumour size can be more accurately equated with the biologic aggressiveness of the disease than with delayed time to diagnosis.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings